Department of Biomedical Sciences, Cihan University-Erbil, Erbil, Kurdistan Region, 44001, Iraq.
Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, 44001, Iraq.
Mil Med Res. 2023 Jul 17;10(1):32. doi: 10.1186/s40779-023-00468-6.
Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade. In the study of cancer, the CRISPR/CRISPR-associated protein (Cas) system opens new avenues into issues that were once unknown in our knowledge of the noncoding genome, tumor heterogeneity, and precision medicines. CRISPR/Cas-based gene-editing technology now allows for the precise and permanent targeting of mutations and provides an opportunity to target small non-coding RNAs such as microRNAs (miRNAs). However, the development of effective and safe cancer gene editing therapy is highly dependent on proper design to be innocuous to normal cells and prevent introducing other abnormalities. This study aims to highlight the cutting-edge approaches in cancer-gene editing therapy based on the CRISPR/Cas technology to target miRNAs in cancer therapy. Furthermore, we highlight the potential challenges in CRISPR/Cas-mediated miRNA gene editing and offer advanced strategies to overcome them.
成簇规律间隔短回文重复序列 (CRISPR) 在过去十年中改变了生物医学研究，并为分析生物医学科学的各个方面提供了全新的模型。在癌症研究中，CRISPR/CRISPR 相关蛋白 (Cas) 系统为我们对非编码基因组、肿瘤异质性和精准医学的认识中曾经未知的问题开辟了新途径。基于 CRISPR/Cas 的基因编辑技术现在可以精确和永久地靶向突变，并为靶向微小非编码 RNA（如 microRNAs (miRNAs)）提供了机会。然而，有效的和安全的癌症基因编辑治疗的发展高度依赖于适当的设计，以对正常细胞无害，并防止引入其他异常。本研究旨在强调基于 CRISPR/Cas 技术靶向癌症治疗中 miRNAs 的癌症基因编辑治疗的最新方法。此外，我们还强调了 CRISPR/Cas 介导的 miRNA 基因编辑中的潜在挑战，并提供了克服这些挑战的先进策略。
